Oregon Medicaid targets expensive hepatitis drug
By JONATHAN J. COOPER - AP - Thu Jul 31, 9:09PM CDT
WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.
Final Glance: Biotechnology companies
AP - Thu Jul 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Thu Jul 31, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Jul 31, 9:37AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Can the Earnings Rebound be Sustained? - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Thu Jul 31, 2:34AM CDT
Can the Earnings Rebound be Sustained? - Earnings Outlook
Can the Earnings Rebound be Sustained? - Earnings Trends
Sheraz Mian - Zacks Investment Research - Thu Jul 31, 2:34AM CDT
Can the Earnings Rebound be Sustained? - Earnings Trends
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Merck, J&J, Baxter Provide Healthy Dividend Stream
at Investor's Business Daily - Wed Jul 30, 6:01PM CDT
Drugmakers aim to help people live healthier lives, but they aren't immune to patent losses. Merck (MRK), which has recently faced a number of patent expirations, on Tuesday reported Q2 sales that slowed for an eighth quarter in a row. But earnings...
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Why Humana (HUM) Stock Is Declining Today
at The Street - Wed Jul 30, 10:58AM CDT
Humana (HUM) shares are down following the release of the company's second quarter earnings results.
Jim Cramer's Mad Dash: Good News for Regeneron
at The Street - Wed Jul 30, 9:45AM CDT
TheStreet's Jim Cramer says Regeneron has developed a breakthrough cholesterol drug while also receiving positive Phase III results for another treatment.
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies
Business Wire - Wed Jul 30, 7:00AM CDT
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences, Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone's broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute using Theraclone's proprietary I-STAR(TM) technology. The I-STAR technology allows for the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biological functions and activities.